Sarasin Partners Llp Lowers stake in Amgen (AMGN)

Amgen (AMGN) : Sarasin Partners Llp reduced its stake in Amgen by 11.92% during the most recent quarter end. The investment management company now holds a total of 1,321,724 shares of Amgen which is valued at $215,348,491 after selling 178,880 shares in Amgen , the firm said in a disclosure report filed with the SEC on Jul 14, 2016.Amgen makes up approximately 3.45% of Sarasin Partners Llp’s portfolio.

Other Hedge Funds, Including , Cutler Group Lp boosted its stake in AMGN in the latest quarter, The investment management firm added 19,849 additional shares and now holds a total of 21,886 shares of Amgen which is valued at $3,513,141. Amgen makes up approx 0.24% of Cutler Group Lp’s portfolio.Chevy Chase Trust Holdings boosted its stake in AMGN in the latest quarter, The investment management firm added 215 additional shares and now holds a total of 677,575 shares of Amgen which is valued at $109,157,333. Amgen makes up approx 0.60% of Chevy Chase Trust Holdings’s portfolio.Ct Financial Advisors boosted its stake in AMGN in the latest quarter, The investment management firm added 550 additional shares and now holds a total of 14,481 shares of Amgen which is valued at $2,332,889. Amgen makes up approx 1.46% of Ct Financial Advisors’s portfolio.Summit Financial Wealth Advisors boosted its stake in AMGN in the latest quarter, The investment management firm added 200 additional shares and now holds a total of 2,334 shares of Amgen which is valued at $376,007. Amgen makes up approx 0.16% of Summit Financial Wealth Advisors’s portfolio.

Amgen closed down -0.35 points or -0.21% at $162.93 with 18,15,610 shares getting traded on Monday. Post opening the session at $163.82, the shares hit an intraday low of $162.79 and an intraday high of $164 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Amgen reported $2.90 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $2.61. The company had revenue of $5527.00 million for the quarter, compared to analysts expectations of $5321.84 million. The company’s revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.48 EPS.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *